 Christina Finlayson
Concepts (188)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 25 | 2017 | 1965 | 1.110 |
Why?
| | Carcinoma, Ductal, Breast | 5 | 2017 | 91 | 0.540 |
Why?
| | Mastectomy, Segmental | 5 | 2017 | 91 | 0.430 |
Why?
| | Receptors, Estrogen | 7 | 2012 | 387 | 0.370 |
Why?
| | Sentinel Lymph Node Biopsy | 3 | 2008 | 118 | 0.330 |
Why?
| | Lymph Nodes | 3 | 2007 | 455 | 0.330 |
Why?
| | Thoracic Vertebrae | 1 | 2007 | 72 | 0.300 |
Why?
| | Mammography | 1 | 2007 | 126 | 0.290 |
Why?
| | Prostheses and Implants | 1 | 2007 | 141 | 0.280 |
Why?
| | Receptors, Progesterone | 4 | 2012 | 325 | 0.240 |
Why?
| | Receptor, ErbB-2 | 3 | 2012 | 320 | 0.240 |
Why?
| | src Homology Domains | 1 | 2003 | 34 | 0.240 |
Why?
| | Estrogens | 3 | 2012 | 328 | 0.210 |
Why?
| | Vitamin E | 1 | 2000 | 116 | 0.180 |
Why?
| | Phytotherapy | 1 | 2000 | 69 | 0.180 |
Why?
| | Postoperative Hemorrhage | 1 | 2000 | 79 | 0.180 |
Why?
| | Reoperation | 2 | 2017 | 557 | 0.160 |
Why?
| | Tamoxifen | 5 | 2012 | 198 | 0.160 |
Why?
| | Neoplasm Staging | 7 | 2010 | 1223 | 0.150 |
Why?
| | Neoadjuvant Therapy | 3 | 2010 | 333 | 0.140 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 66 | 0.140 |
Why?
| | Pelvic Exenteration | 1 | 1996 | 12 | 0.140 |
Why?
| | Pelvic Neoplasms | 1 | 1996 | 20 | 0.140 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 93 | 0.130 |
Why?
| | Carcinoma, Lobular | 2 | 2017 | 56 | 0.130 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 199 | 0.130 |
Why?
| | Hodgkin Disease | 1 | 2016 | 119 | 0.130 |
Why?
| | Antineoplastic Agents, Hormonal | 4 | 2012 | 143 | 0.130 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2010 | 1167 | 0.120 |
Why?
| | Insulin | 1 | 2003 | 2162 | 0.120 |
Why?
| | Signal Transduction | 3 | 2012 | 4709 | 0.110 |
Why?
| | Practice Patterns, Physicians' | 2 | 2017 | 1200 | 0.110 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 38 | 0.110 |
Why?
| | Radiotherapy, Adjuvant | 3 | 2008 | 189 | 0.110 |
Why?
| | Breast | 2 | 2003 | 140 | 0.100 |
Why?
| | Carcinoma in Situ | 1 | 2011 | 45 | 0.100 |
Why?
| | Female | 22 | 2017 | 61564 | 0.100 |
Why?
| | Axilla | 2 | 2007 | 57 | 0.100 |
Why?
| | Practice Guidelines as Topic | 2 | 2017 | 1440 | 0.090 |
Why?
| | Keratin-5 | 1 | 2010 | 47 | 0.090 |
Why?
| | Palliative Care | 1 | 1996 | 629 | 0.090 |
Why?
| | Radiotherapy | 2 | 2008 | 187 | 0.090 |
Why?
| | BRCA2 Protein | 1 | 2009 | 44 | 0.090 |
Why?
| | Estrogen Receptor alpha | 1 | 2010 | 126 | 0.090 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 51 | 0.090 |
Why?
| | Thrombophilia | 1 | 2009 | 68 | 0.080 |
Why?
| | Drug Resistance, Neoplasm | 2 | 2010 | 671 | 0.080 |
Why?
| | Humans | 27 | 2017 | 118972 | 0.080 |
Why?
| | Aromatase Inhibitors | 1 | 2008 | 52 | 0.080 |
Why?
| | Middle Aged | 12 | 2017 | 27617 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2008 | 207 | 0.080 |
Why?
| | Radiotherapy Planning, Computer-Assisted | 1 | 2007 | 120 | 0.070 |
Why?
| | Breast Cyst | 1 | 2006 | 2 | 0.070 |
Why?
| | Cyst Fluid | 1 | 2006 | 27 | 0.070 |
Why?
| | Carcinoma, Papillary | 1 | 2007 | 76 | 0.070 |
Why?
| | Sternum | 1 | 2006 | 17 | 0.070 |
Why?
| | Biomarkers, Tumor | 2 | 2010 | 1059 | 0.070 |
Why?
| | Phosphoproteins | 2 | 2008 | 308 | 0.070 |
Why?
| | Melatonin | 1 | 2006 | 109 | 0.070 |
Why?
| | Carcinoma, Ductal | 1 | 2005 | 12 | 0.070 |
Why?
| | Liver Neoplasms | 1 | 2009 | 527 | 0.060 |
Why?
| | Ki-67 Antigen | 1 | 2005 | 108 | 0.060 |
Why?
| | Combined Modality Therapy | 4 | 2008 | 1166 | 0.060 |
Why?
| | Retroviridae Proteins, Oncogenic | 1 | 2003 | 12 | 0.060 |
Why?
| | Enzyme Inhibitors | 1 | 2008 | 827 | 0.060 |
Why?
| | Bone Neoplasms | 1 | 2006 | 199 | 0.060 |
Why?
| | Oncogene Protein v-akt | 1 | 2003 | 25 | 0.060 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2003 | 58 | 0.060 |
Why?
| | Retrospective Studies | 5 | 2017 | 12978 | 0.060 |
Why?
| | rhoA GTP-Binding Protein | 1 | 2003 | 80 | 0.060 |
Why?
| | Receptor, Insulin | 1 | 2003 | 100 | 0.060 |
Why?
| | Multiple Sclerosis | 1 | 2008 | 384 | 0.060 |
Why?
| | Adult | 11 | 2017 | 31512 | 0.060 |
Why?
| | Proto-Oncogene Proteins p21(ras) | 1 | 2003 | 237 | 0.050 |
Why?
| | Referral and Consultation | 1 | 2007 | 648 | 0.050 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2005 | 527 | 0.050 |
Why?
| | Mitogen-Activated Protein Kinases | 1 | 2003 | 298 | 0.050 |
Why?
| | Neoplasm Recurrence, Local | 1 | 2007 | 900 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 2 | 2007 | 2436 | 0.050 |
Why?
| | Mastectomy, Radical | 1 | 2000 | 2 | 0.050 |
Why?
| | Nurse Anesthetists | 1 | 2000 | 3 | 0.050 |
Why?
| | Phosphorylation | 1 | 2003 | 1633 | 0.040 |
Why?
| | Gynecomastia | 1 | 1998 | 4 | 0.040 |
Why?
| | Immunohistochemistry | 3 | 2008 | 1691 | 0.040 |
Why?
| | Cluster Analysis | 2 | 2012 | 481 | 0.040 |
Why?
| | Endocrine System Diseases | 1 | 1998 | 32 | 0.040 |
Why?
| | Blood Coagulation | 1 | 2000 | 219 | 0.040 |
Why?
| | Survival Rate | 2 | 2008 | 1720 | 0.040 |
Why?
| | Oligonucleotide Array Sequence Analysis | 2 | 2012 | 770 | 0.040 |
Why?
| | Preoperative Care | 1 | 2000 | 332 | 0.040 |
Why?
| | Aged | 5 | 2017 | 19657 | 0.040 |
Why?
| | Margins of Excision | 1 | 2017 | 31 | 0.040 |
Why?
| | Gene Expression Profiling | 3 | 2008 | 1597 | 0.040 |
Why?
| | Mastectomy | 2 | 2007 | 124 | 0.040 |
Why?
| | Ultrasonography | 1 | 2000 | 716 | 0.030 |
Why?
| | Estradiol | 2 | 2010 | 476 | 0.030 |
Why?
| | Consensus | 1 | 2017 | 534 | 0.030 |
Why?
| | Quality Indicators, Health Care | 1 | 2017 | 295 | 0.030 |
Why?
| | Lymph Node Excision | 2 | 2009 | 158 | 0.030 |
Why?
| | Adenocarcinoma | 1 | 2000 | 812 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2017 | 523 | 0.030 |
Why?
| | CD24 Antigen | 1 | 2012 | 21 | 0.030 |
Why?
| | Breast Neoplasms, Male | 1 | 2012 | 31 | 0.030 |
Why?
| | Hyaluronan Receptors | 1 | 2012 | 93 | 0.030 |
Why?
| | Patient Selection | 1 | 1996 | 676 | 0.030 |
Why?
| | Prospective Studies | 1 | 2003 | 6471 | 0.030 |
Why?
| | Mice, SCID | 1 | 2012 | 333 | 0.030 |
Why?
| | Mass Screening | 1 | 1998 | 1052 | 0.030 |
Why?
| | Cell Line, Tumor | 2 | 2010 | 2851 | 0.030 |
Why?
| | Tumor Burden | 1 | 2012 | 274 | 0.030 |
Why?
| | Colorado | 2 | 2017 | 4196 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 1996 | 969 | 0.020 |
Why?
| | Gene Regulatory Networks | 1 | 2012 | 239 | 0.020 |
Why?
| | Biopsy, Needle | 1 | 2011 | 190 | 0.020 |
Why?
| | Mice, Inbred NOD | 1 | 2012 | 574 | 0.020 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 874 | 0.020 |
Why?
| | Prognosis | 2 | 2009 | 3443 | 0.020 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2010 | 106 | 0.020 |
Why?
| | Peptide Mapping | 1 | 2010 | 63 | 0.020 |
Why?
| | Databases, Protein | 1 | 2010 | 60 | 0.020 |
Why?
| | Xenograft Model Antitumor Assays | 1 | 2012 | 740 | 0.020 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 146 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 70 | 0.020 |
Why?
| | Cyclophosphamide | 1 | 2009 | 222 | 0.020 |
Why?
| | Observer Variation | 1 | 2010 | 309 | 0.020 |
Why?
| | Interferon beta-1a | 1 | 2008 | 12 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 126 | 0.020 |
Why?
| | Glatiramer Acetate | 1 | 2008 | 20 | 0.020 |
Why?
| | Neoplastic Stem Cells | 1 | 2012 | 336 | 0.020 |
Why?
| | Databases as Topic | 1 | 2008 | 73 | 0.020 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2009 | 190 | 0.020 |
Why?
| | Perilipin-1 | 1 | 2008 | 16 | 0.020 |
Why?
| | Neoplasm Invasiveness | 1 | 2010 | 462 | 0.020 |
Why?
| | Estrogen Receptor Modulators | 1 | 2008 | 19 | 0.020 |
Why?
| | Interferon-beta | 1 | 2008 | 82 | 0.020 |
Why?
| | S100 Proteins | 1 | 2008 | 35 | 0.020 |
Why?
| | Doxorubicin | 1 | 2009 | 302 | 0.020 |
Why?
| | Perimenopause | 1 | 2008 | 59 | 0.020 |
Why?
| | Androstadienes | 1 | 2008 | 94 | 0.020 |
Why?
| | Mastectomy, Modified Radical | 1 | 2007 | 7 | 0.020 |
Why?
| | SEER Program | 1 | 2008 | 205 | 0.020 |
Why?
| | Lymphatic Metastasis | 1 | 2008 | 307 | 0.020 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2008 | 310 | 0.020 |
Why?
| | Selective Estrogen Receptor Modulators | 1 | 2007 | 26 | 0.020 |
Why?
| | Blotting, Western | 1 | 2010 | 1194 | 0.020 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 1 | 2007 | 58 | 0.020 |
Why?
| | Transcriptome | 1 | 2012 | 756 | 0.020 |
Why?
| | Dehydroepiandrosterone Sulfate | 1 | 2006 | 44 | 0.020 |
Why?
| | Mice, Nude | 1 | 2008 | 663 | 0.020 |
Why?
| | Epidermal Growth Factor | 1 | 2006 | 173 | 0.020 |
Why?
| | Quality of Life | 1 | 1996 | 2366 | 0.020 |
Why?
| | Positron-Emission Tomography | 1 | 2006 | 298 | 0.020 |
Why?
| | Neoplasm Proteins | 1 | 2007 | 401 | 0.020 |
Why?
| | Patient Care Planning | 1 | 2005 | 143 | 0.020 |
Why?
| | Proteomics | 1 | 2010 | 876 | 0.010 |
Why?
| | Transforming Growth Factor beta | 1 | 2006 | 462 | 0.010 |
Why?
| | Chemotherapy, Adjuvant | 1 | 2005 | 360 | 0.010 |
Why?
| | Mice | 2 | 2012 | 15520 | 0.010 |
Why?
| | Carrier Proteins | 1 | 2008 | 726 | 0.010 |
Why?
| | Treatment Outcome | 1 | 2017 | 9342 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 879 | 0.010 |
Why?
| | Postmenopause | 1 | 2005 | 305 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2010 | 2275 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2007 | 1384 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2010 | 2874 | 0.010 |
Why?
| | Phenotype | 1 | 2010 | 3003 | 0.010 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 1390 | 0.010 |
Why?
| | Biopsy | 1 | 2005 | 1079 | 0.010 |
Why?
| | Age Factors | 1 | 2008 | 2995 | 0.010 |
Why?
| | United States | 1 | 2017 | 12555 | 0.010 |
Why?
| | Liver | 1 | 2009 | 1816 | 0.010 |
Why?
| | Apoptosis | 1 | 2010 | 2484 | 0.010 |
Why?
| | Hospitals, Private | 1 | 1999 | 12 | 0.010 |
Why?
| | Hospitals, County | 1 | 1999 | 11 | 0.010 |
Why?
| | Hospitals, University | 1 | 1999 | 172 | 0.010 |
Why?
| | Leydig Cell Tumor | 1 | 1998 | 8 | 0.010 |
Why?
| | Animals | 2 | 2012 | 33381 | 0.010 |
Why?
| | Aged, 80 and over | 1 | 2010 | 6561 | 0.010 |
Why?
| | Infant, Newborn | 1 | 2009 | 5255 | 0.010 |
Why?
| | Male | 3 | 2012 | 57801 | 0.010 |
Why?
| | Testicular Neoplasms | 1 | 1998 | 95 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 5690 | 0.010 |
Why?
| | Antineoplastic Agents | 1 | 2008 | 1974 | 0.010 |
Why?
| | Cost-Benefit Analysis | 1 | 1998 | 554 | 0.010 |
Why?
| | Socioeconomic Factors | 1 | 1999 | 1129 | 0.010 |
Why?
| | Risk Factors | 1 | 2008 | 9000 | 0.010 |
Why?
| | Patient Education as Topic | 1 | 1999 | 699 | 0.010 |
Why?
| | Adolescent | 1 | 1998 | 18480 | 0.000 |
Why?
|
|
Finlayson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|